GHRP-2

Safety Summary

The most reproducible effect in human studies is increased appetite/food intake: all 7 healthy men ate significantly more during GHRP-2 infusion (35.9% increase, P=0.004; PMID 15699539), and 7 of 10 GH-deficient children reported increased appetite during oral treatment PMID 14513874. Formal adverse-event reporting in clinical studies was favorable: no side effects reported in the 7-subject feeding study PMID 15699539, intranasal therapy described as well tolerated in pediatric study PMID 9390009, and no obvious side effects in the 1-year anorexia nervosa case PMID 26401470. A 30-day continuous SC infusion and 12-month oral administration in children also reported no adverse effects (as referenced in PMID 15699539). GHRPs as a class mildly stimulate cortisol and prolactin, with effects described as modest and transient PMID 9186261. The FDA Category 2 listing cites reports of serious adverse events including increased insulin requirement, death of critically ill study subjects, infection, and pancreatitis -- though causality was not established (FDA Category 2 list). GH secretagogues as a class raise concern for decreased insulin sensitivity PMID 28400207. Regulatory analysts cite cortisol and prolactin elevation as concerns for continued Category 2 classification. Community reports (not peer-reviewed) include: elevated resting heart rate (~100 BPM post-injection), significant hunger within 30 minutes, water retention, sleep disruption during initial weeks, and skin improvements. Users note GHRP-2 produces less appetite stimulation than GHRP-6 but more than ipamorelin. Long-term safety data in humans are limited.